LEUVEN, Belgium, August 27 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.
During 2009, ThromboGenics has continued to focus on the activities which are key to its aim of becoming a profitable, integrated company focused on cutting edge ophthalmic medicines. Central to this plan is the Company's lead product, microplasmin, which is in Phase III trials for the treatment of back of the eye disease. Patient recruitment in this Phase III program is running smoothly and the Company expects to report the first results from these studies by mid 2010.
The clinical development of the Company's unique long-acting anticoagulant TB-402, which is in Phase II trials for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery, has progressed more rapidly than originally expected.
Patrik De Haes, CEO of ThromboGenics, said:
"ThromboGenics has seen most of its key programs make significant
progress during the course of 2009. We are very happy with the speed of
patient recruitment in the microplasmin Phase III program. Microplasmin is
central to our aim of building a strong, profitable and integrated company
centered on cutting edge ophthalmic medicines. Given our increasing
confidence in the clinical merits of microplasmin we are now starting to
develop our commercialization plans for this novel product. We are also very
encouraged by the progress of the Phase II program for TB-402, as recruitment
is ahead of schedule. This clinical study has reinforced our view that we
have an attractive out-licensing opportunity for companies keen to enhance
their position in the anti-coagulant therapy market. Our partnership with
|SOURCE ThromboGenics NV|
Copyright©2009 PR Newswire.
All rights reserved